Given that wild-type isoforms account for more than 90% of all GBM, it is now time to capitalize on the knowledge built from mutant IDH1/2 targeting to outline rationale on wild-type IDH enzymes targeting. This evidence concerns the gene IDH1 and glioblastoma.